New gel could soothe painful rash from cancer treatment
Symptom relief
Recruiting now
This study tests a topical gel called HT-001 for treating skin rashes, dryness, and nail problems caused by EGFR inhibitor cancer drugs. About 152 adults on these cancer therapies will apply the gel daily for 6 weeks. The goal is to see if it reduces rash severity and improves qu…
Phase: PHASE2 • Sponsor: Hoth Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC